Webcast ImageWebcast
Q1 2017 BioTime, Inc. Earnings Conference Call (Live)
05/10/17 at 4:30 p.m. ET
Q1 2017 BioTime, Inc. Earnings Conference Call
Wednesday, May 10, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 29, 2014BioTime Appoints Adi Mohanty Chief Operating Officer
Executive Brings Proven Leadership in Biopharmaceutical Product Development and Commercialization to BioTime ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 29, 2014-- BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of Chief Operating Officer of the Company. Mr. Mohanty’s primary respo... 
Printer Friendly Version
December 15, 2014BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discov... 
Printer Friendly Version
December 15, 2014BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic
-OncoCyte’s Proprietary Diagnostic Markers Tested on Patient Samples Collected by Pathologists at Leading US Medical Institution- ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaborati... 
Printer Friendly Version
December 15, 2014BioTime Appoints Angus C. Russell to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors. Shire is a leading global specialty biopharmaceutical company. During Mr. Russell's tenure as Chief Executive Officer of Shire from 200... 
Printer Friendly Version
December 12, 2014BioTime to Host Investor and Analyst Day on December 15, 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15, 2014 at the Harvard Club of New York City. A live webcast of the presentations will begin at 1:15 pm ET and the webcast will conclude by 4:00 pm ET. Presentations will p... 
Printer Friendly Version
December 03, 2014BioTime to Present at the LD Micro VII Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 3, 2014-- BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the LD Micro VII Conference taking place December 2-4, 2014 in Los Angeles, California. Dr. West will provide a corporate update in his presentation on Thursday, December 4, 2014, 4:00... 
Printer Friendly Version
November 10, 2014BioTime Reports Third Quarter Results and Recent Progress
Asterias Biotherapeutics approved for listing on NYSE MKT Asterias’ AST-OPC1 cleared by FDA for Phase 1/2a dose escalation clinical trial for spinal cord injury Cell Cure Neuroscience’s OpRegen® cleared by FDA for Phase 1/2a dose escalation clinical trial for the dry form of age-related macular degeneration Renevia™ cleared for pivotal trial in Europe for treatment of HIV-related lipoat... 
Printer Friendly Version
November 04, 2014BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe
Renevia™ to be utilized in the treatment of HIV-related lipoatrophy, a disorder estimated to afflict more than 3.5 million patients globally Patient enrollment initiated; expected to be completed in 2015 ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 4, 2014-- BioTime, Inc. (NYSE MKT:BTX) today reported that it has received authorization to begin its pivotal human clinical trial of Renevia™ in Europe. In the trial, Renevi... 
Printer Friendly Version
October 09, 2014BioTime, Inc. Closes $31 Million Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 9, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the sale of BioTime common shares. BioTime and the subsidiaries intend to use the net proceeds from their sales to finance clinical trials of products under development, to finance th... 
Printer Friendly Version
October 06, 2014Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 6, 2014-- BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to the Board to fill a vacancy and Mr. Cartt has been nominated for election to the Board at the Company’s upcoming annual shareholders’ meeting, which will be held on November 4. Mr. Mulroy most recently served as Executive Vice President... 
Printer Friendly Version
October 06, 2014BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares
Shares to be sold at the October 2, 2014 closing market share price Funds to be used in part for clinical trials ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 6, 2014-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered direct offering at an offering price of $3.12 per share. The price per share was the closing price of our common shares on the NYSE... 
Printer Friendly Version
October 03, 2014BioTime’s Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute
- Final Study Enrollment Exceeds 600 Patients - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 3, 2014-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte’s collaborators at The Wistar Institute have completed enrollment of a large, multi-site study evaluating a blood-based lung cancer diagnostic test. OncoCyte previously entered into a Sponsored Research Agreement and a Material Transfer Agreement ... 
Printer Friendly Version
September 09, 2014BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 9, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 16th Annual Healthcare Conference at 9:35 a.m. EDT on Wednesday, September 10, 2014. The conference will be held at the New York Palace Hotel in New York City. Dr. West wi... 
Printer Friendly Version
August 28, 2014BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem®-Based Hydrogel for Vocal Fold Scarring
Investigator-initiated clinical trial may follow preclinical studies ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2014-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime’s proprietary HyStem®-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. T... 
Printer Friendly Version
August 12, 2014BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device. Premvia™ is the first FDA-cleared member of BioTime’s HyStem® family of hydrogels, which are designed to mimic the natural structures of the human body’s extracellular matrix. According to the FDA ... 
Printer Friendly Version
August 12, 2014BioTime Announces Second Quarter 2014 Results and Recent Developments
Three cancer diagnostic products in clinical development IND amendment pending for expanded clinical trials of AST-OPC1 Asterias obtains over $12 million in financing and awarded a $14 million grant FDA provides 510(k) premarket clearance for Premvia™ ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the first quar... 
Printer Friendly Version
July 14, 2014BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
- New issued patents add to existing estate of over 600 patents and patent applications worldwide in the emerging field of pluripotent stem cell technology - ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 14, 2014-- BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologi... 
Printer Friendly Version
June 02, 2014BioTime to Present at the Jefferies 2014 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 2, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City. Dr. West will provide a corporate update in his presentation on Thursday, June 5, 2014, 9:00 AM EDT, at the Gr... 
Printer Friendly Version
May 28, 2014BioTime Receives ISO 13485 Certification for Medical Devices
ALAMEDA, Calif.--(BUSINESS WIRE)--May 28, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications. BSI is currently one of the world’s largest independent certification bodies for quality management systems and ISO 13485:2003 is the world’s ... 
Printer Friendly Version
May 12, 2014BioTime Announces First Quarter 2014 Results and Recent Developments
Four products currently in clinical development Three therapeutic products currently in late-stage preparation for clinical development Shares of Asterias subsidiary scheduled to trade publicly in near term LifeMap Solutions subsidiary launched to develop mobile health products ALAMEDA, Calif.--(BUSINESS WIRE)--May 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today reported... 
Printer Friendly Version
May 05, 2014BioTime Raises $6.4 Million in Equity Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--May 5, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately $6.4 million in equity financing. The funds were raised from current long-term investors in the Company and will be used for funding product development, including this year's anticipated pivotal Renevia™ clin... 
Printer Friendly Version
May 01, 2014BioTime Division ESI BIO Launches New Responsive Design Website to the Scientific Community
ESI BIO’s website has been designed to provide the ultimate user-friendly experience whether on a desktop, tablet or mobile device. Allowing customers access to detailed product information and videos with the option to share information across all major social networking sites. ALAMEDA, Calif., May 1, 2014 - BioTime, Inc. through its new research products division ESI BIO, today unveiled a new responsive design website, www.esibio.com, which enriches the online research reagent shoppin... 
Printer Friendly Version
April 24, 2014BioTime to Present at GTC Stem Cell Summit 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the GTC Stem Cell Summit 2014 taking place April 23-25, 2014 in Cambridge, MA. The following are specific details regarding BioTime’s presentation:   ... 
Printer Friendly Version
April 14, 2014BioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 14, 2014-- BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private companies. Mr. Schlachet is the former Chairman and Chief Executive Officer of Syneron Medical Ltd., an Israeli aesthetic medical device company, and he has served as a director of the Tel... 
Printer Friendly Version
April 07, 2014BioTime to Present at 13th Annual Needham Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 7, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 13th Annual Needham Healthcare Conference to be held April 8-9, 2014 in New York City. The following are specific details regarding BioTime’s presentation: ... 
Printer Friendly Version
March 25, 2014BioTime To Present at Regen Med Investor Day March 26 in New York
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 25, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading fin... 
Printer Friendly Version
March 17, 2014BioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 17, 2014-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate Accomplishments BioTime’s subsidiary Asterias Biotherapeutics, Inc. completed the acquisition of stem cell assets from Geron Corporation, i... 
Printer Friendly Version
March 05, 2014BioTime Raises $3.5 Million Through Preferred Stock Offering
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 5, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million. The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a con... 
Printer Friendly Version
March 03, 2014BioTime Provides Financing and Product Development Update
$12.6 Million Raised Since October 1, 2013 in At-the-Market Stock Sales Company is Awarded New NIH SBIR Grant Premvia™ 510(k) Premarket Notification Submitted to FDA for Review ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 3, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering f... 
Printer Friendly Version
February 18, 2014BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 18, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 9th Annual Stem Cell Summit in New York. Dr. West will speak in the session “Disrupting the Pharma Model with Allogeneic Stem Cell Therapies” on February 18, 2014, starting at 9:05 a.m. EST. ... 
Printer Friendly Version
January 13, 2014BioTime Reports Results of Clinical Safety Trial of Renevia™
Renevia™ Appears Safe And Well Tolerated With No Serious Unexpected Adverse Events Observed During The Trial Period Manufacturing and Biocompatibility Information Submitted in a Device Master File to FDA ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 13, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced the completion of a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stab... 
Printer Friendly Version